NEW YORK, Dec. 19, 2025 /PRNewswire/ — Medome is the first AI technology for Personal Health Records for consumers. Patented and clinically validated with thousandsNEW YORK, Dec. 19, 2025 /PRNewswire/ — Medome is the first AI technology for Personal Health Records for consumers. Patented and clinically validated with thousands

Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives

NEW YORK, Dec. 19, 2025 /PRNewswire/ — Medome is the first AI technology for Personal Health Records for consumers. Patented and clinically validated with thousands of real patients, it represents a groundbreaking approach to medical diagnostics, officially launching today to prevent misdiagnoses and improve patient outcomes. Created by physicians and technologists who have personally experienced the consequences of medical errors, Medome leverages advanced AI to bridge the gap between patients and the accurate healthcare they crave.

Medome arose from a tragic loss. Dr. Steven Charlap, a physician and entrepreneur, lost his brother to a preventable cancer medical diagnosis error. These preventable events underscore a devastating reality: nearly 400,000 people in the U.S. die each year due to errors in the diagnostic processes.

Driven by these experiences, the Medome team has harnessed the potential of AI to change the course of patient safety. “Medome exists so no one else dies again from misdiagnosis,” Dr. Charlap says, emphasizing that this platform was built to save lives through superior medical diagnostics.

Medome is not just another patient-facing symptom checker or a basic ai doctor; it is a comprehensive ai doctor diagnosis system. By utilizing sophisticated AI systems to organize, synthesize, and analyze personal information from lab results to family history Medome portrays a complete picture, uncovering patterns that often get missed.

Unlike other tools, Medome performs multiple intense calibrations in real time to narrow down possibilities. Dr. Charlap explains, “Medical knowledge now exceeds human intellectual capabilities. Our goal is not to replace human doctors but to enable patients to assist clinicians by being more contributory to their health journeys.” By using artificial intelligence as the bridge, the platform enhances decisions and identifies safety issues early when they are most effectively treated.

Medome represents a paradigm shift where enabled patients work alongside their providers. By applying proprietary methodologies to complex data, Medome which received support from Stanford, Harvard, the NIH, and the UK’s National Health Services enables patients to exert greater control over their diagnosis and treatment plan.

“We built Medome to save lives and ensure no one has to encounter a physician alone again,” Dr. Charlap concludes.

About Medome

Medome is an ai medical diagnosis and health intelligence platform that consolidates your medical history to provide a personalized treatment plan and prevent crises. It analyzes symptoms against your unique risk profile and distinguishes a local emergency from manageable problems. When you do need urgent care, it instantly generates a comprehensive medical summary to optimize diagnostic processes. Think of it as a medical command center that knows you better than any 15-minute appointment ever could.

Users can learn more at: www.medome.ai

Contact
Medome
media@medome.ai

Photo – https://mma.prnewswire.com/media/2849829/Medome_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medome-launch-heralds-the-end-of-medical-misdiagnoses-and-lost-lives-302647184.html

SOURCE Medome

Market Opportunity
Sleepless AI Logo
Sleepless AI Price(AI)
$0.03636
$0.03636$0.03636
+1.87%
USD
Sleepless AI (AI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies Targeting Orbital Fibroblasts Drive Revenue Growth – ResearchAndMarkets.com

Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies Targeting Orbital Fibroblasts Drive Revenue Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Thyroid Eye Disease Treatments Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The thyroid
Share
AI Journal2025/12/20 04:48
Virtus Equity & Convertible Income Fund Announces Special Year-End Distribution and Discloses Sources of Distribution – Section 19(a) Notice

Virtus Equity & Convertible Income Fund Announces Special Year-End Distribution and Discloses Sources of Distribution – Section 19(a) Notice

HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Equity & Convertible Income Fund (NYSE: NIE) today announced the following special year-end distribution to holders of its
Share
AI Journal2025/12/20 05:30
Fed rate decision September 2025

Fed rate decision September 2025

The post Fed rate decision September 2025 appeared on BitcoinEthereumNews.com. WASHINGTON – The Federal Reserve on Wednesday approved a widely anticipated rate cut and signaled that two more are on the way before the end of the year as concerns intensified over the U.S. labor market. In an 11-to-1 vote signaling less dissent than Wall Street had anticipated, the Federal Open Market Committee lowered its benchmark overnight lending rate by a quarter percentage point. The decision puts the overnight funds rate in a range between 4.00%-4.25%. Newly-installed Governor Stephen Miran was the only policymaker voting against the quarter-point move, instead advocating for a half-point cut. Governors Michelle Bowman and Christopher Waller, looked at for possible additional dissents, both voted for the 25-basis point reduction. All were appointed by President Donald Trump, who has badgered the Fed all summer to cut not merely in its traditional quarter-point moves but to lower the fed funds rate quickly and aggressively. In the post-meeting statement, the committee again characterized economic activity as having “moderated” but added language saying that “job gains have slowed” and noted that inflation “has moved up and remains somewhat elevated.” Lower job growth and higher inflation are in conflict with the Fed’s twin goals of stable prices and full employment.  “Uncertainty about the economic outlook remains elevated” the Fed statement said. “The Committee is attentive to the risks to both sides of its dual mandate and judges that downside risks to employment have risen.” Markets showed mixed reaction to the developments, with the Dow Jones Industrial Average up more than 300 points but the S&P 500 and Nasdaq Composite posting losses. Treasury yields were modestly lower. At his post-meeting news conference, Fed Chair Jerome Powell echoed the concerns about the labor market. “The marked slowing in both the supply of and demand for workers is unusual in this less dynamic…
Share
BitcoinEthereumNews2025/09/18 02:44